Physician profile
Eric M Madren
NPI 1760457089
$650.93
in general payments reported to CMS, 2019-2025
10 companies · $78.70 in 2025
The $78.70 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $42.14 · 2021: $101 · 2022: $160 · 2023: $219 · 2024: $50.29 · 2025: $78.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $348.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $154.99 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $138.86 | 2022-2024 | Vaxelis, Gardasil 9, Gardasil |
| Cranial Technologies, INC | $125.95 | 2020-2023 | Doc Band |
| Glaxosmithkline, LLC. | $57.60 | 2023-2025 | Bexsero, Shingrix, Arexvy |
| Phadia US INC. | $54.89 | 2022-2023 | Immunocap |
| Medtronic, INC. | $45.04 | 2022 | |
| Amarin Pharma, INC. | $27.16 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $17.16 | 2021 | |
| Dexcom, INC. | $16.30 | 2023 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $12.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Madren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.